

Sanjeet S Dadwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2921415/publications.pdf>

Version: 2024-02-01

52
papers

1,646
citations

567281

15
h-index

302126

39
g-index

54
all docs

54
docs citations

54
times ranked

2849
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 377, 2433-2444. | 27.0 | 796 |
| 2 | Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. <i>Cell Reports Medicine</i> , 2021, 2, 100189. | 6.5 | 149 |
| 3 | Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 265-269. | 2.0 | 62 |
| 4 | Recent advances in the molecular diagnosis of mucormycosis. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 845-854. | 3.1 | 60 |
| 5 | Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1983-1994. | 2.0 | 54 |
| 6 | A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 71, 2777-2786. | 5.8 | 53 |
| 7 | A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract. <i>Clinical Infectious Diseases</i> , 2020, 71, 2787-2795. | 5.8 | 44 |
| 8 | Persistent Value of the Stethoscope in the Age of COVID-19. <i>American Journal of Medicine</i> , 2020, 133, 1143-1150. | 1.5 | 43 |
| 9 | A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection. <i>Expert Review of Vaccines</i> , 2018, 17, 889-911. | 4.4 | 42 |
| 10 | Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e322-e327. | 2.0 | 32 |
| 11 | Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. <i>Lancet Microbe</i> , The, 2022, 3, e252-e264. | 7.3 | 29 |
| 12 | Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e321-e330. | 2.0 | 26 |
| 13 | American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 201-211. | 1.2 | 23 |
| 14 | Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2015, 94, 235-242. | 2.2 | 22 |
| 15 | Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study. <i>Transplant Infectious Disease</i> , 2019, 21, e13007. | 1.7 | 19 |
| 16 | DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e773-e781. | 5.8 | 17 |
| 17 | Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1828-1835. | 2.0 | 15 |
| 18 | Infectious complications of immune checkpoint inhibitors in solid organ malignancies. <i>Cancer Medicine</i> , 2022, 11, 21-27. | 2.8 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 292-299. | 2.0 | 13 |
| 20 | Infectious Disease Complications in Patients with Cancer. <i>Critical Care Clinics</i> , 2021, 37, 69-84. | 2.6 | 12 |
| 21 | Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (<sc>HMA</sc>) or liposomal daunorubicin+cytarabine (<sc>CPX</sc>+351). <i>American Journal of Hematology</i> , 2021, 96, E196-E200. | 4.1 | 10 |
| 22 | Variation in Clinical Practice and Attitudes on Antibacterial Management of Fever and Neutropenia in Patients With Hematologic Malignancy: A Survey of Cancer Centers Across the United States. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac005. | 0.9 | 10 |
| 23 | Practice patterns and incidence of adenovirus infection in allogeneic hematopoietic cell transplant recipients: Multicenter survey of transplant centers in the United States. <i>Transplant Infectious Disease</i> , 2020, 22, e13283. | 1.7 | 9 |
| 24 | Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial. <i>PharmacoEconomics - Open</i> , 2021, 5, 469-473. | 1.8 | 8 |
| 25 | Severe Acute Respiratory Syndrome Coronavirus 2-Specific Monoclonal Antibody for the Treatment of Mild to Moderate Coronavirus Disease 2019 in Cancer Patients: A Single-Center Experience. <i>Journal of Infectious Diseases</i> , 2022, 225, 352-354. | 4.0 | 7 |
| 26 | Aseptic Meningitis as a Complication of Daratumumab Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e333-e335. | 0.4 | 6 |
| 27 | Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1697-1703. | 2.0 | 6 |
| 28 | Late-occurring infections in a contemporary cohort of hematopoietic cell transplantation survivors. <i>Cancer Medicine</i> , 2021, 10, 2956-2966. | 2.8 | 6 |
| 29 | Draft Genome Sequence of a Clinical Isolate of <i>Fusarium fujikuroi</i> Isolated from a Male Patient with Acute Myeloid Leukemia. <i>Genome Announcements</i> , 2018, 6, . | 0.8 | 5 |
| 30 | Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1662-1664. | 2.4 | 5 |
| 31 | A Machine-Learning Sepsis Prediction Model for Patients Undergoing Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 711-711. | 1.4 | 5 |
| 32 | Letermovir and maribavir for pan-resistant cytomegalovirus infection in a patient with haematologic malignancy: Consideration for combination therapy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 699-702. | 1.5 | 5 |
| 33 | Safety of Isavuconazonium Sulfate in Pediatrics Patients With Hematologic Malignancies and Hematopoietic Cell Transplantation With Invasive Fungal Infections: A Real World Experience. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, 261-265. | 0.6 | 4 |
| 34 | Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Viral Infections Post-HCT: Results from an Open-Label Cohort of a Phase 2 Trial. <i>Blood</i> , 2021, 138, 1760-1760. | 1.4 | 3 |
| 35 | Update on prevention of cytomegalovirus in hematopoietic cell transplantation. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 63-68. | 3.1 | 2 |
| 36 | Can a Simple Stool Swab Predict Bacteremia in High-Risk Hematopoietic Cell Transplant Recipients?. <i>Clinical Infectious Diseases</i> , 2021, 73, 1266-1267. | 5.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351). <i>Blood</i> , 2020, 136, 37-38. | 1.4 | 2 |
| 38 | Chronic Leptomeningitis and Spinal Intradural Mass Secondary to <i>Alternaria</i> Infection in a Patient with Ventriculoperitoneal Shunt. <i>Case Reports in Infectious Diseases</i> , 2016, 2016, 1-4. | 0.5 | 1 |
| 39 | Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia. <i>Transplant Infectious Disease</i> , 2020, 22, e13233. | 1.7 | 1 |
| 40 | Delayed Cytomegalovirus (cmv) Infection Following Hematopoietic Cell Transplantation (HCT): City of Hope (COH) Experience.. <i>Blood</i> , 2008, 112, 1155-1155. | 1.4 | 1 |
| 41 | Safety, Maximum Tolerated Dose and Immunogenicity of CMV-MVA-Triplex in Healthy Volunteers with or without Prior Immunity to CMV and Vaccinia. <i>Blood</i> , 2015, 126, 3108-3108. | 1.4 | 1 |
| 42 | Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes. <i>Blood</i> , 2018, 132, 3416-3416. | 1.4 | 1 |
| 43 | Updated Analysis: Novel Machine-Learning-Based Sepsis Prediction Model for Patients Undergoing Hematopoietic Stem Cell Transplantation (Early Sepsis Prediction/Identification for Transplant) <i>Tj ETQq1 1 0.784314rgBT /Overlock 10</i> | | |
| 44 | A Randomized Open Label Pilot Study of <i>Clostridium Butyricum</i> Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 334-334. | 1.4 | 1 |
| 45 | 1760. Outcomes of Acyclovir-Resistant Herpes Simplex Virus Infections in Hematologic Malignancies and Hematopoietic Cell Transplant. <i>Open Forum Infectious Diseases</i> , 2019, 6, S647-S647. | 0.9 | 0 |
| 46 | Effect of Vancomycin-Resistance Enterococci Colonization Status Prior to Allogeneic Hematopoietic Cell Transplantation on Transplant Outcomes: A Single Center Retrospective Experience. <i>Blood</i> , 2018, 132, 3386-3386. | 1.4 | 0 |
| 47 | Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience. <i>Blood</i> , 2021, 138, 3037-3037. | 1.4 | 0 |
| 48 | The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type. <i>Blood</i> , 2021, 138, 1776-1776. | 1.4 | 0 |
| 49 | Healthcare Resource Utilization in Transplant Patients Who Are at a Higher-Risk to Develop Cytomegalovirus Infection during Their Primary Transplant-Related Hospitalization. <i>Blood</i> , 2020, 136, 16-17. | 1.4 | 0 |
| 50 | 594. Micafungin Prophylaxis in Acute Myeloid Leukemia Adult Patients Undergoing Induction Chemotherapy. <i>Open Forum Infectious Diseases</i> , 2021, 8, S400-S401. | 0.9 | 0 |
| 51 | 36. Evaluation of a Best Practice Alert (BPA) to Improve <i>Pneumocystis jirovecii</i> Prophylaxis Prescribing in Cancer Patients Receiving High-dose Corticosteroids in an Outpatient Setting. <i>Open Forum Infectious Diseases</i> , 2021, 8, S140-S140. | 0.9 | 0 |
| 52 | 984. Diagnostic Utility of Bronchoalveolar Lavage <i>Pneumocystis jirovecii</i> DNA Polymerase Chain Reaction Assay in Patients with Hematological Malignancies and Hematopoietic Cell Transplantation. <i>Open Forum Infectious Diseases</i> , 2021, 8, S583-S583. | 0.9 | 0 |